Comprehensively, metformin, SGLT2i, and GLP1-RAs have been demonstrated to exert several beneficial effects in prediabetes, reducing inflammation and insulin resistance and inducing weight loss. This evidence concerns the gene GLP1R and prediabetes syndrome.